Clinical Trials - August 21, 2020
First patient dosed in Vaccibody and Nektar Therapeutic trial
The first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating Nektar’s CD122-preferential IL-2 pathway agonist with Vaccibody’s personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). “We’re pleased to advance our collaboration with Vaccibody to evaluate the potential of bempeg given […]
Career choice - July 27, 2020
Director of Business Development
Business development in a clinical stage vaccine company is constantly changing, intellectually challenging and meaningful job that pushes developments in society.
In a new job - August 15, 2019
Vaccibody has appointed a Chief Operating Officer
The company appoints Michael Engsig, a pharmaceutical professional with more than two decades of experience and a successful track record in R&D and commercial functions, as Chief Operating Officer. Before joining Vaccibody, Michael was EVP Drug Development Counselling and Business Development at KLIFO, a Northern-European drug development consultancy with significant experience in partnering with biotech […]
Clinical Trials - April 10, 2017
Vaccibody moves forward with clinical study
Norwegian company Vaccibody is moving forward with the first vaccination of a patient with the human papillomavirus, HPV-virus, in a phase IIa study using the company´s immunotherapy platform. The primary objectives of the phase IIa study are to assess T cell mediated immune responses in the peripheral blood and to evaluate early signs of efficacy. […]
Profiles in Biotech - December 16, 2016
Agnete Fredriksen: “You really need to have drive to make it work”
Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.
Clinical Trials - March 8, 2016
Vaccibody completes enrolment of 12 patients for phase I/II study
Norwegian Vaccibody AS announces enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). As per protocol twelve eligible […]
